Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Synthesis and Biological Assessment of Benzimidazole-Acrylonitrile-1,2,3-Triazole Derivatives As Α-Glucosidase Inhibitors Publisher Pubmed



Hatamfayazi M1 ; Mahdavi M2 ; Moradi Dehaghi S1 ; Khoshneviszadeh M5 ; Iraji A3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Chemistry, Tehran North Branch, Islamic Azad University, Tehran, Iraq
  2. 2. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iraq
  3. 3. Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iraq
  4. 4. Department of Persian Medicine, School of Medicine, Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iraq
  5. 5. Department of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iraq

Source: Bioorganic Chemistry Published:2025


Abstract

In the pursuit of developing potent α-glucosidase inhibitors for managing diabetes, a series of novel benzimidazole-acrylonitrile-1,2,3-triazole derivatives were designed. Sixteen derivatives (12a-p) were synthesized by varying substituents on the phenyl ring of the N-phenylacetamide moiety. Among these, compound 12m emerged as highly effective against α-glucosidase, displaying an IC50 value of 6.0 ± 0.2 μM, significantly outperforming the positive control acarbose (IC50 = 752.0 ± 2.0 μM). The kinetic evaluation revealed that 12m acts as a reversible competitive inhibitor with a Ki value of 4.5 µM. Molecular modeling and dynamics simulations underscored favorable binding energies, highlighting interactions of these compounds with critical amino acids within the α-glucosidase active site. These findings position 12m as a promising candidate for the development of α-glucosidase inhibitors with potent anti-diabetic potential. © 2024 Elsevier Inc.